Related Experiment Video
Updated: Aug 25, 2025

qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue
Published on: July 9, 2014
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases
Valeria Cento1, Luna Colagrossi2, Irene Bossi3
1Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy - valeria.cento@unimi.it.
Insights
Cytomegalovirus (CMV) reactivation may trigger acute coronary syndromes (ACS). CMV-DNAemia was detected in coronary circulation of ACS patients, particularly those without cardiovascular risk factors, suggesting a potential link.
Area of Science:
- Cardiology
- Virology
- Immunology
Background:
- Acute coronary syndromes (ACS) represent a significant global health burden.
- Cytomegalovirus (CMV) reactivation is a potential, yet unproven, trigger for cardiovascular events.
- Understanding the role of CMV in ACS pathogenesis is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the potential role of coronary and systemic cytomegalovirus (CMV) reactivation as a trigger for acute coronary syndromes (ACS).
- To establish a proof-of-concept for CMV involvement in the pathophysiology of ACS.
- To compare CMV prevalence and DNAemia in ACS patients versus non-ACS controls.
Main Methods:
- Prospective enrollment of 193 patients undergoing coronary angiography for ACS (n=136) or non-ACS reasons (n=57).
- Quantification of CMV-DNAemia, CMV-IgG/IgM, and CMV-IgG avidity in matched coronary and peripheral blood samples using RT-PCR and ELISA.
- Inclusion of 17 healthy subjects as controls for CMV seroprevalence comparison.
Main Results:
- High CMV-IgG seroprevalence (91.7%) observed in patients, significantly higher than controls (52.9%).
- Low-level CMV-DNAemia detected in 22.6% of patients, with coronary CMV-DNAemia more frequent in acute ACS cases lacking cardiovascular risk factors (40.0%) compared to chronic cases (10.9%) or acute cases with risk factors (14.3%).
- No evidence of acute CMV infection; findings support a long history of CMV infection.
Conclusions:
- High CMV seroprevalence in patients with heart disease underscores the virus's widespread presence.
- CMV-DNAemia, though uncommon, is present in coronary circulation during ACS, particularly in older individuals and those without traditional cardiovascular risk factors.
- These findings highlight potential avenues for novel interventions targeting CMV in ACS management.
Background:
Acute coronary syndromes (ACS) are a major cause of morbidity and mortality. As cytomegalovirus (CMV) may contribute to cardio-vascular (CV) manifestations, we sought to provide a proof-of-concept for the involvement of coronary and/or systemic CMV-reactivation as a possible ACS trigger.
Methods:
We prospectively enrolled consecutive patients undergoing a coronary angiography for ACS (acute-cases, N.=136), or non-ACS reasons (chronic-cases, N.=57). Matched coronary and peripheral blood-samples were processed for quantification of CMV-DNAemia (RT-PCR), CMV-IgG/IgM, and CMV-IgG avidity (ELISA). Peripheral-blood samples from 17 healthy subjects were included as controls.
Results:
Out of the 193 cases included, 18.1% were aged ≤55 years, 92.5% were Central-European, and 100% immunocompetent. CMV-IgG seroprevalence was 91.7% (95%CI: 87.8-95.6), significantly higher than in healthy-controls (52.9% [95%CI: 29.2-76.5]; P<0.001), yet consistent across age-groups (P=0.602), male/females (P=0.765), and acute/chronic-cases (P=0.157). Median (IQR) IgG titers were 110 (84-163) AU/mL, with 0.62 (0.52-0.72) avidity, supporting a long history of infection. No acute CMV infections were found. In 22.6% (n/N.=40/177) of the IgG-positive cases low-level coronary and/or systemic CMV-DNAemia (always <40 copies/mL) was detected. While no differences in peripheral CMV-DNAemia prevalence were observed nor among cases nor controls, coronary CMV-DNAemia was more frequent in acute-cases without modifiable CV risk-factors (n/N.=4/10; 40.0%), than in chronic-cases (n/N.=6/55, 10.9%; P=0.029), or acute-cases with risk-factors (n/N.=16/112, 14.3%; P=0.058).
Conclusions:
CMV-IgG seroprevalence was high in patients with heart diseases. CMV-DNAemia can be found, although uncommonly, in coronary circulation during an ACS, with increased prevalence in older subjects and in absence of CV risk-factors, identifying possible areas for novel interventions.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis II: Clinical Features and Diagnostic Tests
Coronary Artery Disease III: Clinical Manifestations
Rheumatic Heart Disease I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease IV: Preventive Measures

